Abstract CT246: A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)
Massarelli, Erminia, Goldberg, Zelanna, Cacovean, Alex, Yadav, Bhagyashree, Chen, Guang, Jagasia, Madan, Finckenstein, Friedrich Graf, Fardis, Maria, Sukari, Ammar
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations
Fountzilas, Christos, Cohen, Stacey A., Duvivier, Herbert Leon, Hong, David S., Pedersen, Katrina Sophia, Pisick, Evan P., Sommerhalder, David, Cacovean, Alex, Follit, Courtney, Kowalczyk, Nicole, Munneke, Brian, Tong, Tracy, Morris, Steve, Butler, Thomas, Spira, Alexander I.
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Long, Meixiao, Woyach, Jennifer, Pinilla-Ibarz, Javier, Stephens, Deborah M., Cacovean, Alex, Fiaz, Rana, Goldberg, Zelanna, Jagasia, Madan, Finckenstein, Friedrich Graf, Fardis, Maria, Byrd, John C.
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors
Gettinger, Scott, Kluger, Harriet, Schoenfeld, Adam, Betof-Warner, Allison, He, Kai, Sukari, Ammar, Doger de Speville Uribe, Bernard, Lee, Sylvia, Haefliger, Simon, Goldberg, Zelanna, Cacovean, Alex, Fiaz, Rana, Chen, Guang, Jagasia, Madan, Finckenstein, Friedrich Graf, Fardis, Maria, Jimeno, Antonio
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma
Thomas, Sajeve Samuel, In, Gino Kim, Doger, Bernard, Haefliger, Simon, Martin-Liberal, Juan, Goldberg, Zelanna, Cacovean, Alex, Fiaz, Rana, Chen, Guang, Jagasia, Madan H., Graf Finckenstein, Friedrich, Fardis, Maria, Jimeno, Antonio
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
Ravandi, Farhad, Carraway, Hetty, Khouri, Jack, Kishtagari, Ashwin, Curran, Emily, Schiller, Gary, Yadav, Bhagyashree (Kelshikar), Morris, Steve, Cacovean, Alex, Mourya, Sanchita, Butler, Thomas, Lancet, Jeffrey
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Get full text
Journal Article
A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors
Chesney, Jason Alan, Lutzky, Jose, Thomas, Sajeve Samuel, Nieva, Jorge J., Munoz Couselo, Eva, Martin-Liberal, Juan, Rodriguez-Moreno, Juan Francisco, Cacovean, Alex, Li, Huiling, Fardis, Maria, Gettinger, Scott N.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
P-213 COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Rosenberg, Aaron, Baljevic, Muhamed, Amor, Adrian Alegre, Barrientos, Jacqueline, Bashey, Asad, Baz, Rachid, Burgues, Juan Bergua, Delimpasi, Sosana, Kastritis, Efstathios, Latif, Tahir, Lee, Lisa, Mateos, Maria-Victoria, Morillo, Daniel, Montesinos, Pau, Parrondo, Ricardo, Schiller, Gary, Curran, Emily, Kishtagari, Ashwin, Butler, Thomas, Cacovean, Alex, Follit, Courtney, Mandap, Clarissa, Morris, Steve, Khouri, Jack
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
POSTER: AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)
Ravandi, Farhad, Lancet, Jeffrey, Amor, Adrian Alegre, Badar, Talha, Barrientos, Jacqueline, Bashey, Asad, Burgues, Juan Miguel Bergua, Curran, Emily, Janssen, Jeroen, Jeyakumar, Deepa, Kishtagari, Ashwin, Montesinos, Pau, Morillo, Daniel, Rosenberg, Aaron, Schiller, Gary, Ahmed, Uzma, Cacovean, Alex, Morris, Steve, Follit, Courtney, Mandap, Clarissa, Butler, Thomas, Carraway, Hetty
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)
Ravandi, Farhad, Lancet, Jeffrey, Amor, Adrian Alegre, Badar, Talha, Barrientos, Jacqueline, Bashey, Asad, Burgues, Juan Miguel Bergua, Curran, Emily, Janssen, Jeroen, Jeyakumar, Deepa, Kishtagari, Ashwin, Montesinos, Pau, Morillo, Daniel, Rosenberg, Aaron, Schiller, Gary, Ahmed, Uzma, Cacovean, Alex, Morris, Steve, Follit, Courtney, Mandap, Clarissa, Butler, Thomas, Carraway, Hetty
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
Abstract CT210: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, as single-agent in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM)
Ravandi-Kashani, Farhad, Kishtagari, Ashwin, Carraway, Hetty, Curran, Emily, Schiller, Gary, Cacovean, Alex, Yadav, Bhagyashree, Butler, Thomas, Lancet, Jeffrey
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) with activating KRAS mutations
Cohen, Stacey A., Fountzilas, Christos, Sommerhalder, David, Patel, Sandip, Benson, Ai, He, Kai, Ganti, Apar, Spira, Alex, Yadav, Bhagyashree (Kelshikar), Cacovean, Alex, Morris, Steve, Butler, Tom, Hong, David
Published in Molecular cancer research (01.05.2023)
Published in Molecular cancer research (01.05.2023)
Get full text
Journal Article
A phase 1b/2 study of ibrutinib combination therapy in selected advanced genitourinary and gastrointestinal tumors
Berlin, Jordan, Posadas, Edwin M., Macarulla, Teresa Mercade, Cacovean, Alex, Eckert, Karl, Munneke, Brian, Cole, George W., James, Danelle Frances, Motzer, Robert J.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article